Virnig Beth A, Wang Shi-Yi, Shamilyan Tatyana, Kane Robert L, Tuttle Todd M
Division of Health Policy and Management, School of Public Health, University of Minnesota, A365 Mayo (MMC 729), 420 Delaware St SE, Minneapolis, MN 55455, USA.
J Natl Cancer Inst Monogr. 2010;2010(41):113-6. doi: 10.1093/jncimonographs/lgq024.
The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence of ductal carcinoma in situ (DCIS) as a background paper for the State of the Science Conference on Diagnosis and Management of DCIS.
Published studies were abstracted from MEDLINE and other sources. We include articles published through January 31, 2009; 92 publications were abstracted.
DCIS incidence rose from 1.87 per 100,000 in 1973-1975 to 32.5 per 100,000 in 2005. Increases in incidence were greatest in tumors without comedo necrosis. Incidence increased in all ages but more in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and positive family history. Whereas tamoxifen prevents both invasive breast cancer and DCIS, raloxifene is associated with decreased invasive breast cancer but not decreased DCIS.
Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and the role of chemoprevention for reducing the incidence of DCIS and invasive breast cancer.
美国国立卫生研究院医学应用研究办公室委托进行了一项关于导管原位癌(DCIS)发病率的结构化文献综述,作为DCIS诊断与管理科学现状会议的背景文件。
从MEDLINE及其他来源提取已发表的研究。纳入截至2009年1月31日发表的文章;共提取了92篇出版物。
DCIS发病率从1973 - 1975年的每10万人1.87例升至2005年的每10万人32.5例。无粉刺样坏死的肿瘤发病率增长最为显著。各年龄段发病率均有所上升,但50岁以上女性上升幅度更大。乳腺钼靶检查使用增加可解释部分而非全部发病率上升情况。新发DCIS的风险因素包括年龄较大和家族史阳性。他莫昔芬可预防浸润性乳腺癌和DCIS,而雷洛昔芬与浸润性乳腺癌发病率降低相关,但与DCIS发病率降低无关。
值得进一步研究的科学问题包括乳腺钼靶检查使用与DCIS发病率之间的关系,以及化学预防在降低DCIS和浸润性乳腺癌发病率方面的作用。